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Abstract
Background: Amyloidogenesis is linked to neuroinflammation. The tyrosine-fructose Maillard reaction product, 2,4-
bis(p-hydroxyphenyl)-2-butenal, possesses anti-inflammatory properties in cultured macrophages, and in an arthritis
animal model. Because astrocytes and microglia are responsible for amyloidogenesis and inflammatory reactions in
the brain, we investigated the anti-inflammatory and anti-amyloidogenic effects of 2,4-bis(p-hydroxyphenyl)-2-
butenal in lipopolysaccharide (LPS)-stimulated astrocytes and microglial BV-2 cells.
Methods: Cultured astrocytes and microglial BV-2 cells were treated with LPS (1 μg/ml) for 24 h, in the presence
(1, 2, 5 μM) or absence of 2,4-bis(p-hydroxyphenyl)-2-butenal, and harvested. We performed molecular biological
analyses to determine the levels of inflammatory and amyloid-related proteins and molecules, cytokines, Ab, and
secretases activity. Nuclear factor-kappa B (NF-B) DNA binding activity was determined using gel mobility shift
assays.
Results: We found that 2,4-bis(p-hydroxyphenyl)-2-butenal (1, 2, 5 μM) suppresses the expression of inducible nitric
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as the production of nitric oxide (NO), reactive oxygen
species (ROS), tumor necrosis factor-a (TNF-a), and interleukin-1b (IL-1b) in LPS (1 μg/ml)-stimulated astrocytes and
microglial BV-2 cells. Further, 2,4-bis(p-hydroxyphenyl)-2-butenal inhibited the transcriptional and DNA binding
activity of NF-B–a transcription factor that regulates genes involved in neuroinflammation and amyloidogenesis
via inhibition of IB degradation as well as nuclear translocation of p50 and p65. Consistent with the inhibitory
effect on inflammatory reactions, 2,4-bis(p-hydroxyphenyl)-2-butenal inhibited LPS-elevated Ab42 levels through
attenuation of b- and g-secretase activities. Moreover, studies using signal transducer and activator of transcription
3 (STAT3) siRNA and a pharmacological inhibitor showed that 2,4-bis(p-hydroxyphenyl)-2-butenal inhibits LPS-
induced activation of STAT3.
Conclusions: These results indicate that 2,4-bis(p-hydroxyphenyl)-2-butenal inhibits neuroinflammatory reactions
and amyloidogenesis through inhibition of NF-B and STAT3 activation, and suggest that 2,4-bis(p-hydroxyphenyl)-
2-butenal may be useful for the treatment of neuroinflammatory diseases like Alzheimer’s disease.
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Background
Alzheimer’s disease (AD) is an age-related neurodegen-
erative disease characterized by the accumulation of
beta amyloid (Ab), an insoluble peptide deposited extra-
cellularly in the brain, causing senile plaques [1]. This
hydrophobic polypeptide is the product of proteolytic
cleavage of the amyloid precursor protein (APP). Brains
of patients with AD exhibit a number of pathological
abnormalities, including a profound loss of synapses,
microglial activation, and inflammatory processes [2].
Studies performed in transgenic animals suggest that
inflammation plays an important role in the process of
cerebral amyloid deposition [3,4]. Inflammatory reac-
tions and mediators have been reported to augment
APP expression and Ab formation [5,6] and transcrip-
tionally upregulate mRNA and protein levels and enzy-
matic activity of b-secretase, a key enzyme in the
production of Ab [7]. Recently we and others have also
shown that lipopolysaccharide (LPS), an inducer of
inflammation, can influence Ab deposition [8,9] and
that anti-inflammatory agents prevent Ab deposition in
cultured neuronal cells [9-11], as well as in a mouse
models of AD [9,12]. Moreover, McGeer and colleagues
proposed possible therapeutic effects of anti-inflamma-
tory agents in patients with AD [13]. These observations
strongly suggest that neuroinflammation could be an
important causative contributor in the development
and/or progression of AD, and anti-inflammatory agents
c o u l db ee f f e c t i v ei nd i m i s h i n gt h ep r e v a l e n c eo fA D
through reduction of Ab generation and/or deposition.
Nitric oxide (NO) is a free radical produced by the
inducible NO synthase (iNOS) isoform. Prostaglandins
(PGs), products of cyclooxygenase (COX) are essential
components of the host innate immune and inflamma-
tory responses that may contribute to pathological pro-
cesses, in particular, neurodegenerative diseases such as
multiple sclerosis, Parkinson’s disease, and AD [14]. In
most neurodegenerative disorders, massive neuronal cell
death occurs as a consequence of an uncontrolled neu-
roinflammatory response, where activated astrocytes and
microglia, together with their cytotoxic agents, play a
crucial pathological role [15]. Glial cells, consisting of
astrocytes and microglia, can produce cytokines, reactive
oxygen radicals, NO, and PGs, which lead to exaggera-
tion of the disease processes [16]. Expression of genes
for inflammatory elements such as iNOS and COX-2, as
well as cytokines, can be regulated by activation of
nuclear factor-B( N F - B). There is one NF-BD N A
consensus sequence within the COX-2 promoter [17],
and 2 NF-B DNA consensus sequences within the
iNOS promoter [18], which are responsible for NF-B
DNA-binding activity. Moreover, NF-B DNA consen-
sus sequences are also located in the promoter of neuro-
nal b-secretase (BACE 1). Dysregulation of NF-B, thus,
is associated with many inflammation-associated dis-
eases, as well as the generation of Ab,i m p l y i n gt h a t
appropriate regulation and control of NF-Ba c t i v i t y
would provide a potential approach for the management
of AD, through the reduction of both neuroinflamma-
tion and Ab generation [19]. Signal transducer and acti-
vator of transcription 3 (STAT3) is also a significant
regulator of neuroinflammation, Ab generation [20], and
cytokine-driven NF-B-mediated Ab gene expression
[21].
The Maillard reaction (MR), a well-known, non-enzy-
matic browning reaction, can produce colored or color-
less products from substrates such as glucose-tyrosine,
glucose-lysine, fructose-lysine, ribose-lysine, xylose-argi-
nine, xylose-glycine, and xylose-tryptophan [22-25].
These products have anti-oxidative [22-24,26], anti-
mutagenic [27], anti-carcinogenic [28] and anti-bacterial
effects [29]. Previous studies have shown that LPS treat-
ment of cultured astrocytes causes Ab accumulation
through elevation of b-a n dg-secretase activity and
inflammatory reactions [9]. We have shown that 2,4-bis
(p-hydroxyphenyl)-2-butenal inhibits LPS-elevated
inflammatory reactions in macrophages (unpublished
data). Therefore, in the present study, we investigated
whether 2,4-bis(p-hydroxyphenyl)-2-butenal inhibits
LPS-elevated Ab levels in cultured astrocytes and micro-
glial BV-2 cells, through attenuation of LPS-induced
inflammatory reactions, andi n v e s t i g a t e dp o s s i b l e
mechanisms of anti-amyloidogenesis.
Methods
Chemicals and reagents
LPS (from Escherichia coli 055:B5) was obtained from
Sigma Aldrich (St Louis, MO). Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM), fetal bovine serum, penicillin
and streptomycin were purchased from Invitrogen
(Carlsbad, CA). We used siRNA and AG490 for inhibi-
tion of STAT3 signaling pathway. A non-targeting con-
trol siRNA was purchased from Bioneer (Daejeon,
Korea) and siRNA for STAT3 was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). AG490, a
selective JAK2-specific inhibitor, selectively inhibits
STAT3 phosphorylation. This reagent (Sigma Aldrich)
was dissolved in dimethylsulfoxide (DMSO, Sigma
Aldrich) to a stock concentration of 50 mM, and was
diluted to a final concentration of 50 μMw i t h
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ization of 2,4-bis(p-hydroxyphenyl)-2-butenal has been
described elsewhere [30]. 2,4-Bis(p-hydroxyphenyl)-2-
butenal was prepared as previously reported [30]. In
brief, we prepared 100 ml of fructose-tyrosine mixture
including 0.1 M tyrosine and 0.05 M fructose. MR was
carried out in a temperature-controlled autoclave appa-
ratus (Jisico, Seoul, South Korea) at 130°C for 2 h. After
2 h heating, reaction mixture was filtered through a 0.45
μm membrane and used to isolate the active compounds
through several fractionation steps. The fraction of the
highest a-glucosidase inhibitory activity from each set of
fractions was subjected to the next fractionation step.
Fructose-tyrosine MR products were purified using a
series of solvent fractionations; ethyl acetate (EtOAc), n-
butanol, and water. The EtOAc fraction was subjected
to silica gel column chromatography and eluted with
increasing concentrations of methanol (MeOH) in
dichloromethane (DCM). An A2 fraction via DCM:
MeOH (20:1, v:v) of a first silica gel chromatography
was separated to 23 sub-fractions via a second silica gel
chromatography. Fractions B14 and B15 from the 23
sub-fractions were further purified by semi-preparative
high performance liquid chromatography with a C18
column. The structure is shown in Figure 1. 2,4-Bis(p-
hydroxyphenyl)-2-butenal was dissolved in 0.01%
DMSO, and used at concentrations of 2.5, 5, 10 μg/ml
to treat cultured cells.
Astrocytes and microglial BV-2 cell cultures
Rats were maintained in accordance with the Institu-
tional Animal Care and Use Committee (IACUC) of
Laboratory Animal Research Center at Chungbuk
National University, Korea (CBNU-144-1001-01). Two-
day-old rat pups were ice-anesthetized and decapitated.
After the skin was opened and the skull was cut, the
brain was then released from the skull cavity. After
washing with PBS, the cerebrum was separated from
cerebellum and brain stem, and the cerebral hemi-
spheres were separated from each other by gently teas-
ing along the midline fissure with the sharp edge of
forceps. The meninges were gently peeled from the indi-
vidual cortical lobes and the cortices were dissociated by
mechanical digestion [using the cell strainer (BD Bios-
ciences, Franklin Lakes, NJ, USA)] with DMEM contain-
ing F12 nutrient mixture (F12) (Invitrogen, Carlsbad,
CA). The resulting cells were centrifuged (1,500 rpm, 5
min), resuspended in serum-supplemented culture
media, and plated into 100 mm dishes. Serum-supple-
mented culture media was composed of DMEM supple-
mented with F12, FBS (5%), NaHCO3 (40 mM),
penicillin (100 units/ml), and streptomycin (100 μg/ml).
The cells were incubated in the culture medium in a
humidified incubator at 37°C and 5% CO2 for 9 days. At
confluence (9 days), the flask was subjected to shaking
for 16-18 h at 37°C, the cultures were then treated for
48 h with cytosine arabinoside and the medium was
replaced with DMEM/F12HAM containing 10% FBS.
The monolayer was treated with 1.25% trypsin-EDTA
for a short duration after which the cells were disso-
ciated and plated onto uncoated glass coverslips. The
astrocyte cultures formed a layer of process-bearing,
glial fibrillary acidic protein (GFAP)-positive cells. The
purity of astrocyte cultures was assessed by GFAP-
immunostaining. In our conditions, we found that over
95% of the cells were astrocytes. The cultured cells were
treated with LPS with or without 2,4-bis(p-hydroxyphe-
nyl)-2-butenal for 24 h (for western blotting, Ab levels,
and secretase activity determinations) or for 1 h for NF-
B DNA activity and western blotting for relative pro-
tein expression, or for 8 h for NF-B luciferase activity
assay. Microglial BV-2 cells were maintained with
serum-supplemented culture media of DMEM supple-
mented with FBS (5%), NaHCO3 (40 mM), penicillin
(100 units/ml), and streptomycin (100 μg/ml). BV-2
cells were incubated in culture medium in a humidified
incubator at 37°C and 5% CO2. In a manner similar to
the methods for astrocytes, BV-2 cells were treated with
LPS with or without 2,4-bis(p-hydroxyphenyl)-2-butenal
for 24 h (for Ab level and secretase activity determina-
tions) or for 1 h for NF-B DNA activity and western
blotting for relative protein expression.
Cell viability assay
Cytotoxicity of 2,4-bis(p-hydroxyphenyl)-2-butenal was
evaluated using a WST-8 assay (Dojindo Laboratories,
Tokyo, Japan). WST-8 [2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,
monosodium salt] is reduced by dehydrogenases to give
a yellow-colored soluble product (formazan) in the
Figure 1 Chemical structure of 2,4-bis(p-hydroxyphenyl)-2-
butenal.
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erated is directly proportional to the number of living
cells. In brief, 1 × 10
4 cells per well were plated into 96-
well plates, incubated at 37°C for 24 h, and given a fresh
change of medium. Cells were then incubated with or
without LPS (1 μg/ml) in the absence or presence of
various concentrations of 2,4-bis(p-hydroxyphenyl)-2-
butenal at 37°C for an additional 24 h. At that point, 10
μl of the WST-8 solution was added to the wells and
the incubation was continued for another 1 h. The
resulting color was assayed at 450 nm using a micro-
plate absorbance reader (SunriseTM, TECAN,
Switzerland).
Determination of nitrite production
Astrocytes and microglial BV-2 cells were grown in 96-
well plates and then incubated with or without LPS (1
μg/ml) in the absence or presence of 2,4-bis(p-hydroxy-
phenyl)-2-butenal at various concentrations for 24 h.
Nitrite levels in the supernatant was assessed by Griess
reaction [31]. Each 50 μl of culture supernatant was
mixed with an equal volume of Griess reagent [0.1% N-
(1-naphthyl)-ethylenediamine, 1% sulfanilamide in 5%
phosphoric acid] and incubated at room temperature for
10 min. Absorbance at 540 nm was measured in a
microplate absorbance reader, and a series of known
concentrations of sodium nitrite was used as a standard.
Measurement of ROS
Generation of ROS was assessed by 2,7-dichlorofluores-
cein diacetate (DCFH-DA, Sigma Aldrich), an oxidation-
sensitive fluorescent probe. Intracellular H2O2 or low-
molecular-weight peroxides can oxidize 2,7-dichloro-
fluorescein diacetate to the highly fluorescent compound
dichlorofluorescein (DCF). Briefly, astrocytes were plated
in 6-well plates (5 × 10
4), and subconfluent cells were
subsequently treated with 2,4-bis(p-hydroxyphenyl)-2-
butenal (2.5-10 μg/ml) for 30 min. After the cells were
trypsinized, 1 × 10
4 cells were plated in a black 96-well
plate and incubated with 10 μM DCFH-DA at 37°C for
4 h. Fluorescence intensity of DCF was measured in a
microplate-reader at an excitation wavelength of 485
nm and an emission wavelength of 538 nm.
Measurement of PGE2
Cell media samples were analyzed for PGE2 with kits
purchased from R&D Systems (Minneapolis, MN)
according to manufacturer’s instructions.
Western blot analysis
To obtain total cell lysates, cells were homogenized with
Protein Extraction Solution (PRO-PREPTM, Intron Bio-
technology, Korea), and lysed by a 40 min incubation on
ice. The lysate was centrifuged at 15,000 rpm for 15
min. To investigate protein expression in nuclear
extract, cells were processed using a method for nuclear
extract described in the section on electrophoretic
mobility shift assay (EMSA) below. Equal amounts of
proteins (40 μg) were separated on a SDS/10%-polyacry-
lamide gel, and then transferred to a polyvinylidene
difluoride (PVDF) membrane (GE Water & Process
t e c h n o l o g i e s ,T r e v o s e ,P A ) .B l o t sw e r eb l o c k e df o r2h
at room temperature with 5% (w/v) non-fat dried milk
in Tris-buffered saline Tween-20 [TBST: 10 mM Tris
(pH 8.0) and a 150-mM NaCl solution containing 0.05%
Tween-20]. After a short wash in TBST, membranes
were incubated at room temperature with specific anti-
bodies. Rabbit polyclonal antibodies against iNOS
(1:1,000 dilution, Abcam) and COX-2 (1:1,000 dilution,
Cayman Chemical, Ann Arbor, MI), APP (1:500 dilu-
tion, ABR, Golden, CO, USA), BACE1 (1:500 dilution,
St. Louis, MO, USA), C99 (1:500 dilution, St. Louis,
MO, USA), and rabbit polyclonal antibodies against p65
and IBa (1:500 dilution), and mouse monoclonal anti-
body against p50 (1:500 dilution) (Santa Cruz Biotech-
nology Inc. Santa Cruz, CA) were used in study. Blots
were then incubated with the corresponding conjugated
anti-rabbit or mouse immunoglobulin G-horseradish
peroxidase (Santa Cruz Biotechnology Inc. Santa Cruz,
CA). Immunoreactive proteins were detected with an
ECL western blotting detection system.
Gel electromobility shift assay (EMSA)
Gel shift assays were performed according to the manu-
facturer’s recommendations (Promega, Madison, WI).
Briefly, 5 × 10
6 cells was washed twice with 1× PBS, fol-
lowed by the addition of 1 ml of PBS, and the cells were
transferred into cold Eppendorf tubes. The cells were
spun down at 13,000 rpm for 5 min, and the resulting
supernatant was removed. Cells were suspended in 400
μl of solution A containing 10 mM HEPES, pH 7.9, 1.5
mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride, and vigorously vortexed.
Then, cells were allowed to incubate on ice for 10 min
and centrifuged at 12,000 rpm for 6 min. The pelleted
nuclei were resuspended in solution C (solution A +
420 mM NaCl, 20% glycerol) and allowed to incubate
on ice for 20 min. The cells were centrifuged at 15,000
rpm for 15 min, and the resulting nuclear extract super-
natant was collected in a chilled Eppendorf tube. Con-
sensus oligonucleotides were end-labeled using T4
polynucleotide kinase and [g-
32P] ATP for 10 min at 37°
C. Gel shift reactions were assembled and allowed to
incubate at room temperature for 10 min followed by
the addition of 1 μl (50,000-200,000 cpm) of
32Pe n d -
labeled oligonucleotide and another 20 min of incuba-
tion at room temperature. Subsequently 1 μl of gel load-
ing buffer was added to each reaction and loaded onto a
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formed until the dye was four-fifths of the way down
the gel. Gels were dried at 80°C for 1 h and exposed to
film overnight at -70°C.
Transfection and assay of NF-B luciferase activity
Astrocytes were plated at a density of 1 × 10
5 cells per
24-well plate. After 24 h of growth to 90% confluence,
the cell were transfected with pNF-B-Luc plasmid (5 ×
NF-B; Stratagene, CA) using a mixture of plasmid and
lipofectAMINE PLUS in OPTI-MEN according to man-
ufacturer’s specification (Invitrogen, Carlsbad, CA).
Luciferase activity was measured by using a luciferase
assay kit (Promega) according to the manufacturer’s
instructions (WinGlow, Bad Wildbad, Germany).
Quantitative real-time PCR
For mRNA quantification, total RNA was extracted
using an RNAqueous kit and cDNA was synthesized
from 1 μg of total RNA using a High Capacity RNA-to-
cDNA kit (Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s protocol. Quantitative real-
time PCR was performed using specific primers for
GAPDH (Mm99999915_g1), IL-6 (Mm00446190_m1),
TNF-a (Mm00443258_m1), IL-1b (Mm00434228_m1)
in a 7500 Real-Time PCR System (Applied Biosystems).
Thermocycling conditions include an initial denatura-
tion of 20 s at 95°C, followed by 60 cycles of 95°C for
30 s and 60°C for 30 s). The values obtained for target
gene expression were normalized to GAPDH and quan-
tified relative to expression in control samples. For cal-
culation of relative quantification, the 2-ΔΔCT formula
was used, where -ΔΔCT = (CT,target-CT,GAPDH)
experimental sample - (CT,target-CT,GAPDH) control
sample.
b- and g- Secretase activities assay
The total activities of b-a n dg-secretases (the protein
preparation was same as the western blot) were deter-
mined using a commercially available b-secretase fluor-
escence resonance energy transfer (BACE 1 FRET) assay
kit (PANVERA, Madison, USA) and a g-secretase activ-
ity kit, (R&D systems, Wiesbaden, Germany), respec-
tively, according to the manufactures’ instructions. Each
cell preparation was lysed in cold 1 × cell extraction
buffer (a component of the kit) to a final protein con-
centration of 1 mg/ml. To determine b-secretase activ-
ity, 10 μl of lysate was mixed with 10 μlB A C E 1
substrate (Rh-EVNLDAEFK-Quencher), and then the
reaction mixture was incubated for 1 h at room tem-
perature in black 96-microwell plates. The reaction was
stopped by adding 10 μl of BACE1 stop buffer (2.5 M
sodium acetate). Fluorescence was determined using a
Fluostar galaxy fluorometer (excitation at 545 nm and
emission at 590 nm) equipped with Felix software
(BMG Labtechnologies, Offenburg, Germany). Enzyme
activity was linearly related to fluorescence increases,
and activity is expressed as fluorescence units. All con-
trols, blanks and samples were run in triplicate. To
determine g-secretase activity, 50 μl of lysate was mixed
with 50 μl of reaction buffer. Next, the mixture was
incubated for 1 h in the dark at 37°C after 5 μlo fs u b -
strate was added. Substrate conjugated to the reporter
molecules EDANS and DABCYL was cleaved by g-secre-
tase and released a fluorescent signal. This fluorescence
was measured using a Fluostar galaxy fluorometer (exci-
tation at 355 nm and emission at 510 nm) equipped
with Felix software (BMG Labtechnologies, Offenburg,
Germany). Levels of g-secretase enzymatic activity were
found to be proportional to fluorescence increases, and
g-secretase activity is expressed as fluorescence units.
Fluorescence microscopy
The fixed cells were exposed to following primary anti-
bodies; GFAP and Ab42 (1: 100 dilutions in blocking
serum, Abcam), Iba1 (1:100 dilution in blocking serum,
W a k o )a tr o o mt e m p e r a t u r ef o r1h .A f t e ri n c u b a t i o n ,
the cells were washed twice with ice-cold PBS and incu-
bated with an anti-rabbit or mouse secondary antibody
conjugated to Alexa Fluor 488 or 568 (Invitrogen-Mole-
cular Probes, Carlsbad, CA) at room temperature for 1
h. Immunofluorescence images were acquired using an
inverted fluorescent microscope Zeiss Axiovert 200 M
(Carl Zeiss, Thornwood, NY).
Measurement of Ab levels
Cell lysates (the same preparation of lysates as used for
western blotting) were obtained using protein extraction
buffer containing protease inhibitor, 4-(2-aminoethyl)-
benzene sulfonyl fluoride. Ab42 levels were determined
using specific ELISAs (IBL, Immuno-Biological Labora-
tories Co., Ltd., Japan). In brief, 100 μl of sample was
added to precoated plates and was incubated overnight at
4°C. After washing each well of the precoated plate with
washing buffer, 100 μl of labeled antibody solution was
added and the mixture was incubated for 1 h at 4°C in
the dark. After washing, chromogen was added and the
mixture was incubated for 30 min at room temperature
in dark. Finally, the resulting color was assayed at 450
nm using a microplate absorbance reader (SunriseTM,
TECAN, Switzerland) after addition of stop solution.
Statistical evaluation
Data are presented as mean ± S.E. for three independent
experiments performed in triplicate. Statistical analysis
was performed by one-way ANOVA, followed by a Dun-
nett test as post hoc comparison. Differences were con-
sidered significant at P < 0.05.
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Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on astrocyte
and microglial BV-2 cell viability
Treatment of astrocytes and microglial BV-2 cells with
2,4-bis(p-hydroxyphenyl)-2-butenal resulted in a slight
increase in cell viability at concentrations of 1 or 5 μM,
and showed little reduction (< 20%) in cell viability at 10
μM concentration (Figure 2A and 2B). Furthermore, co-
treatment with 10 μM2 , 4 - b i s ( p-hydroxyphenyl)-2-bute-
nal and 1 μg/ml LPS did not shown significant difference
in viability of astrocytes (Figure 2C) and microglial BV-2
cells (Figure 2D). Thus, in this study, anti-inflammatory
and anti-amyloidogenesis effects were performed with
less than 5 μM of 2,4-bis(p-hydroxyphenyl)-2-butenal.
Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on LPS-
induced ROS, NO, TNF-a, and interleukin (IL)-1b
production in astrocytes and in microglial BV-2 cells
To study the protective effect of 2,4-bis(p-hydroxyphe-
nyl)-2-butenal on LPS-induced activation of astrocytes
and microglial BV-2 cells, the cells were treated with or
without 2,4-bis(p-hydroxyphenyl)-2-butenal in the pre-
sence of LPS (1 μg/ml). Release of ROS and NO was
determined as an indicator of astrocyte and microglial
BV-2 cell activation as well as oxidative stress, and gen-
eration of TNF-a and IL-1b was measured as an indica-
tor of astrocyte and of microglial BV-2 cell activation.
We found that treatment with 2,4-bis(p-hydroxyphenyl)-
2-butenal reduced LPS (5 μg/ml)-induced ROS in astro-
cytes (Figure 3A), and NO generation in astrocytes and
microglial BV-2 cells (Figure 3B and 3C). TNF-a and
IL-1b generation was also reduced in cultured astrocytes
(Figure 3D) and microglial BV-2 cells (Figure 3E) in a
concentration-dependent manner. Notably, these inhibi-
tory effects of 2,4-bis(p-hydroxyphenyl)-2-butenal (5
μM) are comparable to the effects of indomethacin (2
μM), a well-known anti-inflammatory compound.
Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on LPS-
induced iNOS and COX-2 expression
Because iNOS can also be modulated by COX-2, we
investigated whether the inhibitory effect of 2,4-bis(p-
Figure 2 Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on viability of astrocytes and microglial BV-2 cells. Cell viability was evaluated
using a WST-8 assay as described in Methods. Astrocytes (A) and microglial BV-2 cells (B) were incubated with 2,4-bis(p-hydroxyphenyl)-2-butenal
(1-10 μM) in the absence of LPS for 72 h. Astrocytes (C) and microglial BV-2 cells (D) were incubated with 2,4-bis(p-hydroxyphenyl)-2-butenal (10
μM) in the presence of LPS (1 μg/ml) for 96 h. Results are given as a percentage of viable cells related to untreated controls. The data represent
the mean ± S.E. for three independent experiments performed in triplicate.
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BV-2 cell activation and NO production occurs via
inhibition of iNOS and COX-2 gene expression, using
western blot analysis, In agreement with a resting
astrocytic state of non-activation, un-stimulated cells
expressed extremely low levels of iNOS and COX-2
protein. However, iNOS and COX-2 protein expression
was markedly increased in response to LPS (1 μg/ml)
after 24 h. Treatment with 2,4-bis(p-hydroxyphenyl)-2-
butenal (1, 5, 10 μM) caused a concentration-depen-
dent decreases in LPS-induced iNOS expression in
astrocytes (Figure 4A). This result is consistent with
the inhibitory profile of 2,4-bis(p-hydroxyphenyl)-2-
butenal on NO production. A similar inhibitory effect
of 2,4-bis(p-hydroxyphenyl)-2-butenal on LPS-induced
COX-2 expression was also observed in astrocytes
(Figure 4A).
Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on LPS-
induced NF-B luciferase and DNA-binding activities
NF-B controls the expression of mRNA for iNOS and
COX-2, whose products contribute to the pathogenesis
of inflammatory processes. To investigate whether 2,4-
bis(p-hydroxyphenyl)-2-butenal is able to attenuate
LPS-induced NF-B-mediated promoter activity, we
used a luciferase reporter gene expressed under the
control of 5 B cis-acting elements. Astrocytes were
transiently transfected with the NF-B-dependent luci-
ferase reporter construct according to the manufac-
turer’s specifications (Invitrogen). Cells were then
treated with LPS (1 μg/ml) or co-treated with LPS and
2,4-bis(p-hydroxyphenyl)-2-butenal for 8 h. Treatment
with 2,4-bis(p-hydroxyphenyl)-2-butenal resulted in a
concentration-dependent suppression of luciferase
activity induced by LPS (Figure 4B). To investigate
Figure 3 Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on LPS-induced ROS and NO release, and expression of cytokines in astrocytes
and microglial BV-2 cells. Cells were treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 2, 5 μM) of 2,4-bis(p-
hydroxyphenyl)-2-butenal, at 37°C for 24 h. Intracellular ROS levels were determined by measuring DCF fluorescence (A). NO level was
determined by Griess reaction, as described in Methods, in supernatants from astrocytes (B) and microglial BV-2 cells (C). mRNA levels for TNF-a
and IL-1b were determined by real-time PCR, as described in Methods, in astrocytes (D) and microglial BV-2 cells (E). Values represent means ±
SD for three independent experiments performed in triplicate. * indicates significantly different from LPS treated group (P < 0.05).
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Page 7 of 15whether 2,4-bis(p-hydroxyphenyl)-2-butenal can also
inhibit NF-B DNA-binding activity, astrocytes were
co-treated with LPS and 2,4-bis(p-hydroxyphenyl)-2-
butenal for 60 min, this being the time after which
maximal activation of NF-B is observed following LPS
treatment (data not shown). Nuclear extracts from co-
treated cells were prepared and assayed for NF-B
DNA-binding by EMSA. LPS induced strong NF-B
binding activity in cultured astrocytes, which was
inhibited by co-treatment with 2,4-bis(p-hydroxyphe-
nyl)-2-butenal (Figure 4C).
To elucidate the mechanism of inhibition of 2,4-bis(p-
hydroxyphenyl)-2-butenal on LPS-induced NF-B, trans-
location of p50 and p65 as well as IBa degradation
were examined. 2,4-Bis(p-hydroxyphenyl)-2-butenal pre-
vented the LPS-induced increase in nuclear transloca-
tion of p50 and p65 in astrocytes, in a concentration-
dependent manner. 2,4-Bis(p-hydroxyphenyl)-2-butenal
Figure 4 Effects of 2,4-bis(p-hydroxyphenyl)-2-butenal on protein expressions of iNOS and COX-2, and on NF-B-dependent luciferase
activity and NF-B DNA binding activity in astrocytes and microglial BV-2 cells. Astrocytes (A) and microglial BV-2 cells (E) were treated
with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, 10 μM) of 2,4-bis(p-hydroxyphenyl)-2-butenal, at 37°C for 24 h. Equal
amounts of total protein (40 μg/lane) were subjected to 10% SDS-PAGE, and the expression of iNOS and COX-2 were detected by western
blotting using specific antibodies. b-Actin protein was used here as an internal control. Similar results were obtained from at least three different
sets of experiment. Astrocytes were transfected with a p-NF-B-Luc plasmid (5 × NF-B), and then treated with LPS (1 μg/ml) either alone or
with 2,4-bis(p-hydroxyphenyl)-2-butenal (1, 2, 5 μM) for 37°C for 8 h. Luciferase activity was then determined as described in Methods (B).
Astrocytes (C) and microglial BV-2 cells (F) were treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, 10 μM) of 2,4-
bis(p-hydroxyphenyl)-2-butenal at 37°C for 1 h. Activation of NF-B was investigated using EMSA as described in Methods. Nuclear extracts from
astrocytes treated with LPS alone (1 μg/ml) or with 2,4-bis(p-hydroxyphenyl)-2-butenal (1, 2, 5 μM) and LPS were subjected to DNA binding
reaction with
32P end-labeled oligonucleotide specific to NF-B. Specific DNA binding of the NF-B complex is indicated by an arrow. Similar
results were obtained from at least three different sets of experiments. Equal amounts of nuclear extract (40 μg) were subjected to 10% SDS-
PAGE. Nuclear translocation of p50 and p65, and degradation of IB were detected by western blotting using specific antibodies. b-Actin protein
was used here as an internal control (D). Values represent the mean ± S.E. for three independent experiments performed in triplicate, and each
luciferase activity was calibrated using the amount of protein. * indicates significantly different from the LPS-treated group (P < 0.05).
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4 D ) .M o r e o v e r ,w ea l s of o u n dt h a t2 , 4 - b i s ( p-hydroxy-
phenyl)-2-butenal prevented LPS-induced iNOS and
COX-2 expression (Figure 4E) as well as NF-Bb i n d i n g
activity (Figure 4F) in microglial BV-2 cells. These
results indicate that 2,4-bis(p-hydroxyphenyl)-2-butenal
inhibits LPS-induced activation of NF-B via inhibition
of both IBa degradation as well as p50 and p65 trans-
location into the nucleus. These inhibitory effects of 2,4-
bis(p-hydroxyphenyl)-2-butenal on NF-B activity, and
iNOS and COX-2 expression, are also comparable to
the effects of indomethacin (2 μM).
2,4-Bis(p-hydroxyphenyl)-2-butenal prevents LPS-induced
amyloidogenesis
The effect of inflammation on amyloidogenesis in vitro was
also investigated, because neuro-inflammation can cause
amyloid generation, and microglia and astrocytes are a
major source of neuro-inflammation. Astrocytes and
microglia lend both mechanical and metabolic support to
neurons, regulating the environment in which they func-
tion. To determine the relationship between neuro-inflam-
mation and amyloidogenesis, we investigated whether the
anti-inflammatory effect of 2,4-bis(p-hydroxyphenyl)-2-
butenal could result in anti-amyloidogenesis. As shown in
Figure 5A, when unstimulated, the cells expressed low
levels of APP, b-site APP cleavage enzyme (BACE) and
C99 protein, whereas the expressions of BACE and C99
proteins increased in response to LPS (1 μg/ml) after 24 h.
In addition, 2,4-bis(p-hydroxyphenyl)-2-butenal also
decreased LPS-induced Ab42 secretion into the culture
media of astrocytes (Figure 5B). Consistent with the expres-
sion of these proteins, activation of b-a n dg-secretases,
which are the rate-limiting enzymes in Ab generation, was
Figure 5 Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal one x p r e s s i o no fB A C E 1 ,C 9 9a n dA b42, secretase activity and Ab42 level.
Expressions of BACE1, Ab42 and C99 were detected by western blotting using specific antibodies in astrocytes (A) and microglial BV-2
cells (E). Each blot is representative of three experiments. b-Actin protein was used here as an internal control. *p < 0.05 indicates significantly
different from the LPS-treated group. Co-treatments with 2,4-bis(p-hydroxyphenyl)-2-butenal and LPS for 24 h were used. Media were collected
to determine Ab42 secretion by ELISA from astrocytes (B) and microglial BV-2 cells (F). Values represent the mean ± S.E. of three independent
experiments with triplicate. The activities of b-secretase and of g-secretase were assessed using commercially available assay kits as described in
Methods (C and D). Values represent mean ± S.E. for three independent experiments performed in triplicate. * indicates significantly different
from LPS treated group (p < 0.05).
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phenyl)-2-butenal in a concentration-dependent manner
(Figure 5C and 5D). In microglial BV-2 cells, we also found
that 2,4-bis(p-hydroxyphenyl)-2-butenal inhibited LPS-
induced expression of BACE1, C99 and Ab (Figure 5E) as
well as Ab level in a concentration-dependent manner (Fig-
ure 5F). Since activation of astrocytes is implicated in the
activation of b-secretase, we investigated whether the num-
bers of activated (GFAP-positive) astrocytes and accumula-
tion of Ab (Ab42-postive cells) were concomitantly
increased by LPS, and whether 2,4-bis(p-hydroxyphenyl)-2-
butenal would reduce astrocyte activation, thereby reducing
Ab-levels. To demonstrate this more clearly, cells immu-
noreactive for both GFAP and Ab42 were identified using a
double immunofluorescence method. The co-reactive cell
number for both markers was markedly increased by LPS,
but was lowered by 2,4-bis(p-hydroxyphenyl)-2-butenal
treatment (Figure 6A). Moreover, to determine if treatment
by 2,4-bis(p-hydroxyphenyl)-2-butenal inhibits LPS-
induced amyloidogenesis, we investigated the effects of 2,4-
bis(p-hydroxyphenyl)-2-butenal in another neuroglial cell
type, microglial BV-2 cells. The co-reactive cell number for
Figure 6 Expression of activation markers (GFAP for astrocytes and Iba1 for microglia) and Ab42 in astrocytes and in microglial BV-2
cells, observed by double-fluorescence. Confocal microscope observation was performed as described under in Methods. Cultured astrocytes
were incubated with anti-GFAP and anti-Ab42 primary antibodies (A), and the microglial BV-2 cells were incubated with anti-Iba1 and anti-Ab42
primary antibodies (B). Fluorescence was developed using Alexa 568-conjugated anti-rabbit and Alexa 488-conjugated anti-mouse secondary
antibodies. Images of astrocytes double-labeled with GFAP (red) and Ab42 (green) antibodies show the fluorescent antibody staining separately
and merged. Images of microglial BV-2 cells double-labeled with Iba1 (red) and Ab42 (green) antibodies show the fluorescent antibody staining
separately and merged.
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accumulation (Ab42-positive cells) was increased by LPS,
but was lowered by 2,4-bis(p-hydroxyphenyl)-2-butenal
treatment (Figure 6B). These results further indicate that
the amyloidogenic pathway can be promoted by neuro-
inflammatory stimulation, and the anti-inflammatory effect
of 2,4-bis(p-hydroxyphenyl)-2-butenal can result in anti-
amyloidogenesis.
Effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on STAT3
activities
STAT3 cooperates with NF-B in controlling the expres-
sion of genes contributing to inflammatory processes, as
well as amyloidogenesis. To investigate whether 2,4-bis(p-
hydroxyphenyl)-2-butenal can prevent LPS-induced
STAT3 activity, astrocytes and microglial BV-2 cells were
treated with LPS (1 μg/ml) or co-treated with LPS and
2,4-bis(p-hydroxyphenyl)-2-butenal for 24 h. LPS-induced
STAT3 activity (phosphorylation), which was markedly
inhibited by co-treatment with 2,4-bis(p-hydroxyphenyl)-
2-butenal in astrocytes and microglial BV-2 cells in a con-
centration-dependent manner (Figure 7A and 7B).
Involvement of the STAT3 pathway in the inhibitory
effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on LPS-
induced neuroinflammation and amyloidogenesis
To further examine the mechanisms regulating neuroin-
flammation and amyloidogenesis by STAT3 and NF-B,
Figure 7 Effects of 2,4-bis(p-hydroxyphenyl)-2-butenal on STAT3 activation in cultured astrocytes and in microglial BV-2 cells. The cells
were treated with 1 μg/ml of LPS alone, or with LPS plus different concentrations (1, 5, 10 μM) of 2,4-bis(p-hydroxyphenyl)-2-butenal at 37°C for
1 h. Equal amounts of total proteins (40 μg/lane) were subjected to 10% SDS-PAGE, and activation of STAT3 (phosphorylation) was detected by
western blotting using specific antibodies in astrocytes (A) and in microglial BV-2 cells (B). To block the STAT3 pathway, cells were treated with
the STAT3 inhibitor AG490 (50 μM) or with 50 nM siRNA for STAT3 for 1 h prior to treatment with 2,4-bis(p-hydroxyphenyl)-2-butenal. Effect of
2,4-bis(p-hydroxyphenyl)-2-butenal on NF-B DNA binding activity in astrocytes (C) and microglial BV-2 cells (D), and Ab42 level in astrocytes (E)
and microglial BV-2 cells (F). For determination of Ab1-42 levels, cells were treated with 1 μg/ml of LPS alone, or with LPS plus different
concentrations (1, 5, 10 μM) of 2,4-bis(p-hydroxyphenyl)-2-butenal at 37°C for 24 h. Values are mean ± S.E. for three experiments performed in
triplicate. * indicates significantly different from LPS treated group (P < 0.05).
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STAT3 in astrocytes and microglial BV-2 cells activated
by LPS, and investigated the participation of the STAT3
pathway in neuroinflammation and amyloidogenesis.
2,4-bis(p-hydroxyphenyl)-2-butenal inhibited Ab pro-
duction and NF-B activity induced by LPS treatment
in astrocytes. These inhibitory effects were abolished by
down-regulation of STAT3 expression with siRNA and
with the pharmacological STAT3-specific inhibitor
AG490 (50 μM) in cultured astrocytes (Figure 7C and
7E) and microglial BV-2 cells (Figure 7D and 7F). These
findings indicate that activation of STAT3 by 2,4-bis(p-
hydroxyphenyl)-2-butenal may not only inhibit neuroin-
flammation but also prevent neuro-inflammation-
induced Ab production in astrocytes and microglial BV-
2 cells.
Discussion
Epidemiological and genetic evidence has shown that an
inflammatory process contributes to AD pathology. We
have previously shown that there is a convincing link
between neuro-inflammatory reactions and amyloido-
genesis, and that anti-inflammatory agents prevent neu-
roinflammation as well as amyloidogenesis [9,32,33]. In
the present in vitro study, we confirmed that genes
involved in inflammation and amyloidogenesis are con-
comitantly increased by LPS treatment; however, 2,4-bis
(p-hydroxyphenyl)-2-butenal prevented LPS-induced
neuroinflammation and amyloidogenesis. These anti-
inflammatory and anti-amyloidogenic effects may be
related to inhibition of NF-B and STAT3 activity by
2,4-bis(p-hydroxyphenyl)-2-butenal. Consequently, the
results presented in this stu d yi n d i c a t et h a t2 , 4 - b i s ( p-
hydroxyphenyl)-2-butenal cou l db eu s e f u lf o rt h et r e a t -
ment and/or prevention of AD through its anti-neuroin-
flammatory properties.
By means of in vivo studies, we and others had
recently showed that LPS can influence Ab deposition
[8,9] and that anti-inflammatory agents prevent Ab
deposition [11,33]. Ibuprofen, a commonly used, non-
steroidal anti-inflammatory drug (NSAID), reduces Ab
levels, Ab burden, and brain inflammation in a mouse
model of AD (Tg2576) [34], and indomethacin, given to
Tg2576 mice, also reduces insoluble Ab40 and Ab42
levels in hippocampus [12]. Ibuprofen also decreases
cytokine-stimulated Ab production in human neuronal
cells and astrocytes [10]. The present data show that
severe neuroinflammation, as evaluated by COX-2 and
iNOS expression, and expression of BACE and C99 pro-
teins are increased in astrocytes in response to LPS.
However, 2,4-bis(p-hydroxyphenyl)-2-butenal decreased
expression of BACE and C99, as well as Ab42 secretion,
in LPS-stimulated cells. These 2,4-bis(p-hydroxyphenyl)-
2-butenal-induced reversals of LPS-induced changes
were accompanied by reductions in gene expressions for
iNOS and COX-2, and consequent decreases in NO and
ROS production, as well as decreased IL-1b and TNF-a
generation. It is noteworthy that TNF- a has been
shown to increase production of Ab [ 3 5 ] .W eh a v ea l s o
reported co-elevated expression of Ab42 and COX-2, as
well as of TNF-a and IL-1b, in presenilin 2-mutant AD
transgenic mice, and these expressions are prevented by
an anti-inflammatory compound, 4-O-methylhonokiol
[32]. Our present results suggest that 2,4-bis(p-hydroxy-
phenyl)-2-butenal also has anti-neuroinflammatory
effects, and that these effects result in inhibition of amy-
loidogenesis induced by LPS.
The mechanism by which 2,4-bis(p-hydroxyphenyl)-2-
butenal prevents amyloidogenesis is unclear. Because
APP is first cleaved by b-secretase at its b-cleavage site,
generating membrane-bound C99 whose subsequent
proteolysis by g-secretase produces Ab42,w ee x a m i n e d
the effect of 2,4-bis(p-hydroxyphenyl)-2-butenal in the
absence or presence of LPS on b- and g- secretase activ-
ity. Consistent with the effects on Ab42 generation, as
well as BACE and C99 expression, LPS-induced
increases in b-a n dg-secretase activities were prevented
by 2,4-bis(p-hydroxyphenyl)-2-butenal. The inflamma-
tory cytokines IL-1b, IL-6, TNF-a and TGF-b have been
shown to augment APP expression [36,37] and Ab for-
mation [35], and these processes may be related to the
activation of transcriptional upregulation of b-secretase
mRNA, protein and enzymatic activity [7]. TNF-a,I L -
1b and IFN-g stimulate g-secretase and consequently
control Ab generation [38]. Rogers et al. [39] have
shown that primary inflammatory cytokines enhance
APP gene expression at the transcriptional level through
the well-characterized IL-1-responsive element of APP
mRNA. Thus, LPS-enhanced inflammatory cytokines
could influence APP processing and/or secretase activity
(enhancement of b-a n dg-secretases), thereby affecting
amyloidogenesis. These findings suggest that one
mechanism by which 2,4-bis(p-hydroxyphenyl)-2-butenal
prevents amyloidogenesis is due, in part, to a decrease in
LPS-induced production of inflammatory cytokines,
which may activate b- and g-secretases.
Even though cytokine reduction, following 2,4-bis(p-
hydroxyphenyl)-2-butenal treatment could influence
secretases involved in amyloidogenesis induced by LPS,
the signaling involved is poorly understood. It is note-
worthy that the APP and BASE1 genes promoters contain
a potential NF-B recognition site [40-46], thus activation
of NF-B, an important transcription factor involved in
the expression of many inflammatory genes induced by
LPS, could also directly affect APP promoter activity.
Therefore, the inhibition of NF-B by 2,4-bis(p-hydroxy-
phenyl)-2-butenal could play a significant role in reduction
of amyloidogenesis, as well as neuroinflammation induced
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kines increase the expressions of IL-1b, TNF-a and COX-
2, and markedly increase phosphorylation of STAT3 in
primary cultures of rat microglia [47]. Several studies have
shown that STATs have been involved in amyloidogenesis
through the modulation of secretases. Cho et al. showed
that IFNg-induced BACE1 expression is mediated by acti-
vation of the JAK2 signaling pathway, an upstream path-
w a yo fS T A T s ,a n db yd i r e c tb i n d i n go fS T A T 1t ot h e
BACE1 promoter in astrocytes [5]. In our study, 2,4-bis(p-
hydroxyphenyl)-2-butenal-induced inhibition of LPS-
induced Ab production and NF-B activity in astrocytes
and microglial BV-2 cells was abolished by down-regula-
tion of STAT3 expression with siRNA and with the phar-
macological STAT3-specific inhibitor AG490. These
findings indicate that activation of STAT3 by 2,4-bis(p-
hydroxyphenyl)-2-butenal may not only inhibit neuroin-
flammation but also prevent neuro-inflammation-induced
Ab production in cultured astrocytes and microglial BV-2
cells. In addition, blocking NF-Bb y2 , 4 - b i s ( p-hydroxy-
phenyl)-2-butenal is critical for the neuroinflammatory
and amyloidogenic effects of 2,4-bis(p-hydroxyphenyl)-2-
butenal. Moreover, blocking STAT3 abolished the inhibi-
tory effect of 2,4-bis(p-hydroxyphenyl)-2-butenal on NF-
B and amyloidogenesis induced by LPS. These results
suggest that STAT3-dependent NF-B inactivation may
be a critical signal in the anti-neuroinflammation and anti-
amyloidogenesis of 2,4-bis(p-hydroxyphenyl)-2-butenal as
seen in Figure 8.
Inflammatory processes play a critical role in the
pathogenesis of many human diseases. Macrophage
overproduction of inflammatory mediators such as cyto-
kine and NO, for example, have also been implicated in
neuroinflammatory diseases such as AD [48]. Neuroglia,
including astrocytes and microglia, play a pivotal role in
regulating aspects of inflammation in the central ner-
vous system. A convincing link between the neuro-
inflammatory reaction and amyloidogenesis has been
well demonstrated, and anti-inflammatory agents can
concomitantly prevent neuroinflammation as well as
amyloidogenesis. Our present data indicate that 2,4-bis
(p-hydroxyphenyl)-2-butenal, a new product from a tyr-
osine-fructose Maillard reaction could be useful for
treatment and/or prevention of neuroinflammatory dis-
eases such as AD.
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